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Multidrug resistance (MDR) is characterized by the occurence of cross-resistance of a
broad range of structurally and functionally unrelated drugs []. Drugs which are
involved in MDR belong to the group of natural drugs, such as the anthracyclines
(doxorubicin, daunorubicin), vinca alkaloids (vincristine, vinblastine),
epipodophyllotoxins (etoposide), and taxanes (paclitaxel). Several mechanisms are
involved in MDR, such as decreased toposisomerase II enzyme levels or increased
glutathione (GSH) and glutathione S-transferase levels [2]. One of the most well-
known mechanism is the overexpression of P-glycoprotein (P-gp), encoded by the
MDRI gene. P-gp is a 170 kDa transmembrane drug efflux pump,belonging to the
ATP-binding cassette (ABC) superfamily [3].
P-gp is extensively expressed in the human body, namely in the adrenal cortex, the
intestinal mucosal cells, the biliary hepatocytes, the renal proximal tubule epithelium,
the pancreatic ductulus, the pregnant uterus, the gastrointestinal epithelium, the
blood-capillaries of the brain and the testes, and in CD34+ bone marrow stem cells [4,
5]. Furthermore, P-gp can be present on membranes in several tumor types [6]. The
function of the drug elflux pump P-gp is most likely to protect these organs against
endogcnous and exogenous toxins.
In rodents P-gp expression is encoded by two genes, namely the mdrl a and the mdrlb
gene. Considering the distribution of these genes in rodents, it is suggested that these
two genes accomplish the same role as the MDR1 gene in humans.
Another drug efflux pump, which is involved in MDR is the 190 kDa muitidrug
resistance associated protein (MRP), encoded by the MRP, gene. This was firstly
described by Cole et ol ir a MDR small cell lung carcinoma cell l ine without P-gp
expression in which the MRP gene was overexpressed t6l. MRP, is expressed in
nearly all organs and tn several tumor types. BesidelvlRP,, otherhomologues ol flris
gene are known. MRP2 (cMOAT), which is mainly expressed at the canalicular
membrane of hepatocy'tes ll vivo, is involved in the transport of anionic conjugates
into bile. In addition, in vitro studies demonstrated that the functional transport of
MRP2 is equal to MRP,. MRP-. most likely is mainly expressed in the liver. MRP.,
gene expression is only low in a few tissues such as bladder, tonsil, lung and kidney
while MRP. is expressed in nearly all tissues of the human body [7]. Only from MRP,
and MRP. the function is defined. Drugs can be transported by MRP, as well as
MRP, after conjugation or co-transport with GSH. To modulate MRP mediated drugs
resistance, buthionine sulfoximine can be used, which results in intracellular GSH
depletion.
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Overexpression of the P-gp and MRP drug efflux pumps on tumor membranes,
tht result in MDR in human tumors. To circumvent this resistant phenotype,
eral modulators fbr P-gp, such as cyclosporin A are potentially available for
rical use. These modulators are also substrates fbr P-gp and are able to compete
h cytostatic drugs for the drug efflux pump. The result is that the P-gp mediated
nsport of c)'tostatic dr-ugs is inhibited, and the concentration of the cytostatic drug
the cell is increased. However, even large randomized studies with P-gp blockers in
Jition to chemotherapeutic drugs show disappointing results [8-ll]. These may
rtly be due to the fact that it is difficuit to have a proper patient selection. For
rper patient selection, knowledge of functionality of P-gp and MRP, might be
lpful. In this thesis. several experiments where the functional transport of P-gp and
RP, is studied by PET and planar irnaging are described.
In chapter I a review is described giving an overview of measurement P-gp and
RP functionality with PET and SPECT. For SPECT studies several studies with
'Tc-complexes, such as """'Tc-sestamibi and ""'Tc-disofenin and fbr PET, studies
ith "C-radiolabeled P-gp strhstrates are discussed.
To study functional P-gp transport with PET. two "C radiolabeled P-gp substrates
rve been developed. In chapter 2 the labeling of the chemotherapeutic agent
runorubicin and the calcium channel blocker verapamil with "C is described. Both
.diolabeled P-gp substrates were evaluated in vitro and in vivo. l' 'Cldaunorubicin
as synthesized from ["C]diazornethane with an aldehyde precursor, followed by
.ild alkaline hydrolysis. ["Clverapamil was synthesized by a reaction of
rClmethyliodide and N-nor-methylverapamil. Labeling with Ir'C] has the advantage
,at the native compound is available to study pharmacokinetics with PET. With
Lese radiolabeled P-gp substrates the cellular accumulation in an ovarian carcinoma
:ll l ine (42780) and its P-gp overexpressing subline (A2780AD) were studied. The
:llular accumulation of Ir'C]daunonrbicin and Ir'Clveraparnil were respectively l6
rd 4-5 fold higher in 42780 than in A27B0AD.
The chapters 3 and 4 describe visualization of P-gp function in vivo.
r chapter 3 imaging of the P-gp function and the effects of a modulator on this
rnction in mdrla gene disrupted rnice (mdrla(-/-) mice.) and wild type mice
ndrla(+/+) mice) was evaluated. Ex v,ivo biodistribution studies revealed 9.5-fold
gher [rrC]verapamil levels in the brain and 3.4-fold higher levels in the testes of
drla(J-) mice than in mdrla(+/+) mice. The IrrC]verapamil levels were dose-
:pendently increased by the P-gp blocker cyclosporin A in mdrla(+/+) mice. No
odulating effects of cyclosporin A were found in the mdrla(-/-) mice. In vh,o
:sitron camera data showed lower Ir'C]verapamil levels in the brain of mdrla(+/+)
ice than in mdrla(-/-) mice. Tirne activity curves demonstrated that [rrC]verapamil
:cumulation in the brain of mdrla(+i+) ntice was increased by cyclosporin A to
vels comparable with those in rndrla(-/-) mice, indicating that reversal of P-gp
rediated eff-lux can be monitored by PET.
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Chapter 4 describes the results obtained with ['rC]verapamil and
IrrC]daunorubicin in a 2-sided turnor bearing rat. Rats were inoculated with GLC.
cells in one flank and with the MDRI-gene transfected P-gp overexpressing subline
GLC.,/P-gp in the other flank. Biodistribution studies demonstrated higher
accumulation of IrrClverapamil and IrrC]daunorubicin in GLC* than in the GLC'/P-
gp tumors. The decreased accumulation of radioactivity in the GLCr/P-gp tumors was
completely rnodulated by cyclosporin A. In vivo positron camera data of
IrrC]verapamil kinetics and modulating effects with cyclosporin A showed that P-gp
function and its reversal can be visualized non-invasively.
In chapter 5 a compartment model was developed and evaluated to study P-gp
facilitated kinetics and its modulation in rat brain. The results were optimal described
by a 2-compartment model, where the influx was defined by passive diffusion and the
efflux was defined by a combination of passive diffusion and active non-competitive
Michaelis-Menten kinetics. This model allows description of P-gp facilitated
t ranspor t  in  te rms o f  cV, , , , , .  tpmol .n r l - r .m inr )  and k .o  {min ' I t .  F i rs t l y .  assu tn ing  a
conelation between P-gp mediated transport and drug resistance. this might be of
clinical interest in e.g. acquired drug resistance during tumor treatment. In that case,
an increase in P-gp facilitated transport. expressed in tenns of Vn,".. rnay give
information about drug resistance during chemotherapeutic treatment. Secondly,
comparison of P-gp mediated eft-lux in terms of Vu,", at different doses of viuious
modulators, may give insight in the efficiency of modulation.
Chapter 6 describes the drug distribution and the kinetics of a bolus injection of
the amine drug [rrClverapamil in solid tumors and in several tissues in the human
body. It was demonstrated that the [""C]verapami) uptake in t)rc )ung wds
approximately 40Vo of the iniected dose, possibly due to binding of ["C]verapamil to
serotonin transpofiers in the lung. The ['rC]veraparnil half'-l ives in the lungs were
46.2 min, in the heart 73.8 min. and in the tumor 23.7 nrin. which is indicatir,'e for a
relatively fast verapamil etflux from tumor tissue. Therefore. this rapid tumor etflux
of bolus verapamil should be taken into consideration in clinical studies where
verapamil modulation is used in solid tumors patients.
Chapter J and 8 described several experiments with y-ernitting compounds to
study the transpoft tunction of P-gp and MRP in vitro and in vivo.
Chapter 7 describes an in y,itrc study in which it is shown that """'Tc-sestamibi is a
substrate for both the P--qp and MRP, drug efflux pump. It was already known that
"'"'Tc-sestalnibi was a substrate fbr P-gp. Along several ines it was shown 1ho1 '<)'{i'r1.-
sestamibi is also a substrate fol MRP,. Accumulation and efflLrx studies were
performed in a small cell lung carcinoma cell line (GLCr) and in its doxorubicin-
resistant MRP1, but not P-gp overexpressing sublines (GLC.1/ADR) as well as in the
non-small cell carcinoma cell l ine (Sl) and its MRP, -transf'ected subline (Sl-MRP).
In the GLC* cell lines and in the SI-MRP cell line the accumulation of een)Tc-
sestamibi was decreased with increasing MRP expression and after depletion of GSH
r47
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the cellular ee"'Tc-sestamibi concentration was increased. Sensitivity testing showed
cross-resistance of e'rTc-sestamibi in GLCr/ADR,50, versus GLC, and a synergistic
effect on vincristine cltotoxicity in GLC_,/ADR,.,,,.
In chapter 8 the substrate specificity of e'r"'Tc-sestamibi and e"'"Tc-disofenin for P-
gp and MRP was investigated. Furthennore, the possibility to discriminate in vivo
between MRP- and P-gp facilitated transport was evaluated. """'Tc-sestamibi is
normally used in the clinic to study myocard perfusion and """'Tc-disofenin for
diagnostic imaging of hepatobilary disorders. To study whether '''""Tc-disofenin is a
substrate for P-gp and/or MRP', accumulation studies were performed in GLCr,
GLCr/ADRrs,,, &rd GLCr/P-gp cells. ""'"Tc-disofenin cellular accumulation was lower
in GLC*/ADR,.,,, than in GLC*. The accumulation of ""'"Tc-disofenin in GLC.,/P-gp
and GLC., was equal. Bile secretion of ""'"Tc-sestamibi in MRP. deficient GY/TR
Wistar rats and in normal Wistar rats was equal, while L"r")Tc-disofenin transpoft was
lower inGY/TR than in Wistar rats. Transport activity of "e"'Tc-sestamibi and 'e"'Tc-
disofenin was decreased after GSH depletion. Gamma-camera experiments with
"e'"Tc-sestamibi and ee'"Tc-disofenin in GY/TR Wistar rats and in normal Wistar rats
visualized a delayed liver excretion of ee"'Tc-disofenin in GY/TR rats compared to
normal Wistar rats, while radionuclide activity of """'Tc-sestamibi was equal in both
types of rats. ""'"Tc-disofenin was also studied in healthy volunteers and in a Dubin-
Johnson patient. Due to a defect in the MRP, drug efflux pump, camera data
visualized that in the Dubin-Johnson patienl fte l'repatobiliary transport of qqmTc-
disofenin was delayed compared to healthy volunteers.
CoNcTUSIONS AND FUTURN PERSPBCTIVES
The occurrence of drug resistance is a major obstacle in the clinical treatment of
cancer patients. Several mechanisms leading to drug resistance xist, and one of them
is MDR. Various mechanisms are underlying MDR, namely l) increased expression
of drug efflux pumps (P-gp and MRP), 2) increased expression of LRP, 3) reduced
expression of the topoisomerase II enzyme. Focussing on P-gp and MRP, it might be
helpful to know the status of drug efflux pumps for a more successful treatment of
clinical response to cancer. Much research has been initiated to get more insight in the
conrribution of P-gp and MRP in MDR and the possibility to inhibit transport activity
of these pumps. One potential way to overcome MDR is to treat cancer patients with
chemotherapeutic drugs in combination with relative non-toxic modulating agents.
Until now. clinical randomized studies demonstrated lirnited to no effect in solid
tumors after addition of modulators [8-l l]. One of the reasons for this poor clinical
outcome may be due to the patient selection. Therefore, to select a patient group who
will benefit frorn MDR modulators combined with cytostatic agents, it is useful to
study the functional transporl of P-gp and MRP. As diagnostic tool, PET and planar
148
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scintigraphy with radiolabeled substrates are interesting techniques which might
allow a non-invasive, quantitative study of the transport kinetics by drug efflux
pumps. It can be concluded from the results of the studies described in this thesis,
that visualization of the P-gp and MRP function in vivo may be a helpful tool in the
design of modulator studies in the clinic. To define the exact role of these new
functional diagnostic tests, further research including studies in various tumor types is
necessary. It would be interesting to know the protein expression of drug efflux
pumps in these tumors, to study whether there is a good conelation between P-gp and
MRP expression and efflux. When a correlation between protein levels and drug
efflux would exist, it might give more insight in the transpofi functionality of P-gp
and MRP in vivo.lt is of relevance to study whether efflux activity of P-gp and MRP
can both be efficiently inhibited by modulators, such as biricodar [12].
When the best diagnostic tool for measuring P-gp functionality is developed, the
most suitable radiolabeled tracer should be found for MDR studies in vivo. Until now.
it is unclear which tracer is most useful to study P-gp and MRP functionality.
The development of a diagnostic tool to measure P-gp mediated kinetics in
patients, might have a broad impact in further research e.g. the blood-brain banier.
The blood-brain barrier consists of an endothelial cell layer in the brain microvessels
and maintain homeostasis. Due to the presence of tight junctions between endothelial
cells in the brain, transpoft of hydrophylic drugs is limited. Normally, transpofi of
drugs can be predicted by their lipophilicity. However, due to P-gp expression in the
blood-brain barrier, the brain uptake is low for several clinical relevant and
hydrophylic drugs. For instance, several CNS-active drugs (chlorpromazine,
clomipramine, phenytoin) and HIV protease inhibitors (saquinavir, indinavir) interact
with P-gp. Therefore P-gp overexpression might be an underlying mechanism for
drug therapy resistance in certain psychiatric and AIDS patients. Furthermore, for P-
gp modulation, co-administration with these drugs in combination with other P-gp
substrates (dexamethasone, cyclosporin A) may improve drug delivery to the brain
[13, l4]. However, sometimes after co-medication eurotoxicity is observed. This is
decribed many times for transplantation patients, where central neurotoxicity was
observed due to the treatment with dexamethasone and cyclosporin A [15, 16].
Besides P-gp, recently MRP has also been localized in the blood-brain banier [7-
201. Therefore, novel insights in the pathophysiology and in the pharmacology of
drugs would be gained if the P-gp and MRP function in the blood-brain barrier could
be visualized and quantified with a non-invasive imaging technique such as PET.
When the function of the drug efflux pumps in the blood-brain barrier can be
measured quantitatively, a modulator can be administered in an effective dose due to
inhibit the transport function of these drug efflux pumps. Then the concentration of
clinical relevant drugs which work on the central nervous system can be increased in
the brain. In this way, the measurement of the function of the drug efflux pumps in





central nervous system. Finally, fiom this thesis it can be concluded that insight in
mechanisms of MDR in tumors may be helpful in the insight of other physiological
and pathological processes in which P-gp and MRP are involved.
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